{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"16 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.90","upperLimit":"1.00","value":"0.99"}]}],"title":"32 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.87","upperLimit":"0.99","value":"0.96"}]}],"title":"48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.81","upperLimit":"0.96","value":"0.91"}]}],"title":"64 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.78","upperLimit":"0.94","value":"0.88"}]}],"title":"80 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.78","upperLimit":"0.94","value":"0.88"}]}],"title":"96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.74","upperLimit":"0.92","value":"0.85"}]}],"title":"112 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.71","upperLimit":"0.89","value":"0.82"}]}],"title":"128 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.71","upperLimit":"0.89","value":"0.82"}]}],"title":"144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.69","upperLimit":"0.88","value":"0.80"}]}],"title":"160 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"0.84","value":"0.75"}]}],"title":"176 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.57","upperLimit":"0.80","value":"0.70"}]}],"title":"192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.77","value":"0.67"}]}],"title":"208 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.77","value":"0.67"}]}],"title":"224 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.77","value":"0.67"}]}],"title":"240 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.77","value":"0.67"}]}],"title":"256 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization. Duration of the overall clinicohematologic response was pre-specified in the protocol to be analyzed for the ruxolitinib arm only considering the study design which allowed crossover for the BAT arm beginning at Week 32.","reportingStatus":"POSTED","timeFrame":"256 Weeks","title":"Duration of The Overall Clinicohematologic Response","type":"SECONDARY","unitOfMeasure":"probability"}